Title
Category
Credits
Event date
Cost
Recorded Presentations from the NCCN 2025 Nursing Program: Advancing Oncology Nursing™
$0.00
The NCCN 2025 Nursing Program: Advancing Oncology Nursing™ covers essential updates in clinical oncology practice, including emerging treatment modalities and patient management strategies. Participants will explore evidence-based approaches to supportive care, focusing on symptom management and improving quality of life for patients with cancer. The program also addresses the importance of self-care for oncology nurses, providing practical techniques for managing stress and preventing burnout in this challenging field.
Venous Thromboembolism Management in Malignancy
  • Venous Thromboembolic Disease
  • 0.75 ANCC contact hours
  • 0.75 Participation
$0.00
Clinical staff should be knowledgeable in factors that enhance VTE risk and be able to counsel patients regarding risk factors that are modifiable. They should also understand appropriate prophylaxis regimens for high-risk patients and be educated on the signs associated with the diverse subtypes of VTE and their best courses of treatment.
Updates in Melanoma: A Focus on Neoadjuvant Approaches
  • Melanoma
  • 0.75 ANCC contact hours
  • 0.75 Participation
$0.00
With new regimens emerging as viable options for neoadjuvant therapy, clinicians should be aware of the changing landscape in initial cutaneous melanoma treatment options. It will be essential for the clinician to identify patients who would benefit from neoadjuvant intervention versus a more traditional surgical or systemic therapy approach.
CRS and ICANS Management in CAR T/Bispecific Antibody Therapies
  • Management of Immunotherapy-Related Toxicities
  • 0.75 ANCC contact hours
  • 0.75 Participation
$0.00
As these therapies continue to evolve, it is imperative that nursing policies are created/revised and shared with nursing staff to remain up to date on current clinical practice for these complications. With continued education and reinforcement of protocols, nurses can positively impact patient outcomes.
Updates in the Management of Biliary Tract Cancers
  • Hepatobiliary Cancers
  • 0.50 AAPA Category 1 CME credit
  • 0.50 ACPE contact hours
  • 0.50 AMA PRA Category 1 Credit™
  • 0.50 ANCC contact hours
  • 0.50 Participation
$0.00
The advent of novel targeted agents has led to a shift in the treatment paradigm of advanced biliary tract cancers. In recent years, multiple targeted agents were FDA-approved, including tumor-agnostic agents. As such, molecular profiling has become increasingly useful and can potentially help guide treatment decisions.
Newer Approaches to Treatment of Bladder Cancer
  • Bladder Cancer
  • 1.00 AAPA Category 1 CME credit
  • 1.00 ACPE contact hours
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 ANCC contact hours
  • 1.00 Participation
$0.00
Recent approvals and clinical trial results continue to enhance treatment options for both BCG-resistant non-muscle invasive bladder cancer and locally advanced/metastatic bladder cancer. Clinicians should be knowledgeable in these recent updates as well as understand how to apply them to their clinical practice.
Advances in Antiemesis Management for Patients with Cancer
  • Supportive Care Topics
  • 0.75 AAPA Category 1 CME credit
  • 0.75 ACPE contact hours
  • 0.75 AMA PRA Category 1 Credit™
  • 0.75 ANCC contact hours
  • 0.75 Participation
$0.00
Recent clinical trials continue to enhance available data on the use of olanzapine for emesis prevention in parenteral anticancer agents with high and moderate emetogenic risk as well as for breakthrough treatment and an alternative to dexamethasone for delayed anticancer induced nausea/vomiting. Clinicians should be aware of these updates and how they apply to appropriate patients.
Treatment for Pleural and Peritoneal Mesothelioma
  • Mesothelioma
  • 0.75 AAPA Category 1 CME credit
  • 0.75 ACPE contact hours
  • 0.75 AMA PRA Category 1 Credit™
  • 0.75 ANCC contact hours
  • 0.75 Participation
$0.00
Recent phase 3 clinical trial data suggest that surgery and chemotherapy may lead to worse survival outcomes than chemotherapy alone for certain patients with pleural mesothelioma. Additionally, data on other systemic therapy regimens for the treatment of mesothelioma have been recently published.
Advances in the Treatment of Non-Metastatic Non-Small Cell Lung Cancer
  • Lung Cancers
  • 1.00 AAPA Category 1 CME credit
  • 1.00 ACPE contact hours
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 ANCC contact hours
  • 1.00 Participation
$0.00
Clinicians should be aware of all the available systemic therapy regimens as well as updated guideline recommendations on biomarker testing and treatment to ensure that patients with non-metastatic NSCLC receive the most appropriate treatments.
Management of Immune Checkpoint Inhibitor-Related Toxicities
  • Management of Immunotherapy-Related Toxicities
  • 1.00 AAPA Category 1 CME credit
  • 1.00 ACPE contact hours
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 ANCC contact hours
  • 1.00 Participation
$0.00
The landscape of cancer care has undergone a dramatic shift, due to the availability and increased use of immunotherapy agents such as immune checkpoint inhibitors (ICIs). As more patients become eligible to receive ICIs, clinicians need to be able to recognize immune-mediated adverse events (irAEs) and remain informed about the most up-to-date strategies for managing these toxicities.

Pages